By Nicole Gray
Endo pushes further into generics with $8 billion Par Pharma buy
Endo International Plc (ENDP.O) said it would buy Par Pharmaceutical Holdings Inc from private-equity firm TPG Capital for about $8 billion, including debt, to become a top-five generic drugmaker by sales in the United States.
Par Pharma was acquired by TPG for $1.9 billion in 2012 and since then has shifted focus to make generics that are difficult to make and administer. Such generics offer higher margins than others. Read More
Lpath eyes job cuts after a crushing AMD failure
The drug, isonep, failed to meet its goals of improving vision in AMD patients who don’t respond to standard anti-VEGF therapies, sending Lpath’s shares down more than 80%. Now the company plans to “restructure its workforce and conduct a strategic evaluation of its research and development programs,” Lpath said in a statement, looking to save money as it plots its next move. Read More
New Weight Loss Product Gets FDA Approval for Obese
New Weight Loss Product Gets FDA Approval for Obese. More. The V-Block is an FDA approved pacemaker-like device, available to those severely …Watch